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The Relationships between Survivals and Early Salvage Androgen 
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Androgen deprivation therapy (ADT) is one salvage treatment used when prostate-spe-
cific antigen (PSA) recurs after radical prostatectomy (RP), especially in high-risk pros-
tate cancer (PC) patients. However, the optimal timing for salvage ADT (SADT) is still 
unclear. In this study, we analyzed the efficacy of early SADT for non-organ confined 
PC. We investigated pathologically confirmed, non-organ confined PC patients who re-
ceived SADT for PSA recurrence after RP. Patients with distant metastasis, those with 
lymph node involvement confirmed by lymph node dissection, and those who received 
neo-adjuvant or adjuvant therapy were excluded. Early SADT was defined as ADT ini-
tiated before PSA levels reached 0.5 ng/ml from the nadir PSA level after RP. 
Univariable and multivariable Cox regression analyses were performed for distant 
metastasis-free, PC-specific, and overall survival. Data from 345 patients were 
analyzed. The median follow-up duration was 82 months. The median PSA level was 
10.9 ng/ml. Patients with T3b or T4 stage cancers represented 24.9% of the cohort; those 
with a Gleason score ≥9 represented 15.1%. The 10-year distant metastasis-free sur-
vival, PC-specific survival and overall survival were 87.1%, 92.0%, 80.9%, respectively. 
In univariable and multivariable Cox regression analyses, SADT that was initiated 
when PSA levels were less than 0.5 ng/mL was significantly associated with improved 
distant metastasis-free survival, PC-specific survival, and overall survival in non-or-
gan confined PC. Early SADT initiated in patients with PSA levels <0.5 ng/mL was 
associated with increased distant metastasis-free survival, PC-specific survival, and 
overall survival in non-organ confined PC after RP. 
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Androgen deprivation therapy (ADT) for prostate cancer 
(PC) was first introduced decades ago.
1
 The efficacy and 
timing of this therapy for various stages of PC has been in-
vestigated by many researchers. In the current National 
Comprehensive Cancer Network (NCCN) or EAU-ESTRO- 
SIOG guidelines, ADT is typically reserved for advanced 
PC.
2,3
 Men who received delayed ADT had more symptoms 
and were more likely to die from PC. However, immediate 
initiation of ADT improved survival in patients with meta-
static PC.
4
 Immediate ADT as an adjuvant therapy after 
radical prostatectomy (RP) for node-positive PC showed 
improved survival.
5
 However, the effect of ADT on node- 
negative PC is still unclear. In localized PC, men who re-
ceived primary ADT for PC did not exhibit improved overall 
survival (OS) over those receiving conservative manage-
ment.
6
 Otherwise, ADT afterlocal curative treatment of-
fers benefits, especially in high-risk PC. In a recent system-
atic review, early ADT had benefits for PC patients with 
short PSA doubling times and high Gleason scores.
7
 Never-
theless, data regarding optimal timing of ADT as a salvage 
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TABLE 1. Baseline patient characteristics
n=345 Median IQR IQR




Prostate volume measure by TRUS (mL) 30 23.0-38.0
PSA (ng/mL) 10.9 7.1-17.2
PSA (categorical) (n/%)
   <20 281 81.4%
   ≥20 62 18.6%
D’Amico risk classification (n/%)
   Low 28 8.1%
   Intermediate 101 29.3%
   High 216 62.6%
Pathologic T stage (n/%)
   T3a 259 75.1%
   T3b or T4 86 24.9%
Pathologic Gleason score (n/%)
   <9 293 84.9%
   ≥9 52 15.1%
Positive surgical margin (n/%) 261 75.7%
PSA at salvage ADT (ng/mL) 0.24 0.14-0.96
Type of ADT (n/%)
   LHRH agonist or antagonist 
      with anti-androgens
199 57.7%
   LHRH agonist or antagonist only 101 29.3%
   Anti-androgens only 45 13.0%
PSA doubling time at ADT (months) 3.4 2.0-6.7
Salvage radiotherapy (n/%) 97 28.1%
BCR after salvage ADT (n/%) 166 48.1%
10 year distant metastasis free survival 87.1%
10 year prostate cancer specific survival 92.0%
10 year overall survival 80.9%
ADT: androgen deprivation therapy, BCR: biochemical re-
currence, BMI: body mass index, IQR: interquartile range, 
LHRH: luteinizing hormone-releasing hormone, PSA: prostate 
specific antigen, PSM: positive surgical margin, TRUS: trans-
rectal ultrasonography.
treatment is still limited, despite various suggested 
regimens. Moreover, although early ADT could delay bio-
chemical and clinical disease progression, the effect of ear-
ly ADT on survival is still unclear.
8
 In this study, we inves-
tigated efficacy of early salvage ADT (SADT), or ADT that 
was initiated before PSA levels reached 0.5 ng/mL, from na-
dir in non-organ confined PC following RP. We analyzed the 
impact of SADT on survival outcomes.
MATERIALS AND METHODS
After approval by the Institutional Review Board (No. 
4-2017-1206), we retrospectively investigated PC patients 
who underwent RP within the Yonsei University Health 
System between 1998 and 2014. We included lymph 
node-negative, non-organ confined PC patients after RP 
and who received ADT as a salvage treatment. Non-organ 
confined PC was classified as T3 or 4 N0 PC after RP. 
Salvage treatment was defined as ADT or radiotherapy 
that was provided after PSA elevation from the recorded 
nadir PSA level after RP. We considered adjuvant therapy 
to be ADT orradiotherapy provided in the absence of an ob-
served PSA elevation after RP. Patients who received 
neo-adjuvant or adjuvant therapy were excluded. Patients 
with metastatic PC at diagnosis and lymph node-positive 
PC were also excluded. The type and timing of SADT was 
determined by physician’s discretion. Patient’s age, body 
mass index (BMI), prostate volume measured by trans-rec-
tal ultrasonography, PSA level, risk classification, PSA 
doubling time, and pathological outcomes were assessed as 
clinical and pathological variables. The D’Amico risk clas-
sification
9
 was used for risk assessment. PSA doubling 
time was calculated by comparing PSA level at initiation 
of SADT and the last PSA level measured before SADT was 
initiated. Data on mortality and cause of deathwere ob-
tained from Yonsei Cancer Registry Center database at 
Yonsei University Health System. TNM stage was de-





We defined early SADT as ADT that was initiated before 
a change inPSA level reached +0.5 ng/mL over the nadir 
PSA level recorded after RP. We defined late SADT as ADT 
provided after PSA level increased more than 0.5 ng/mL 
over the nadir PSA level. Distant metastasis was defined 
as metastasis to bone, non-regional lymph nodes, or other 
sites as reported by radiological evaluation. We defined 
PC-specific mortality as death caused by PC or PC-related 
complications. 
Cox regression analyses were performed to investigate 
associations between each clinical parameter and sur-
vival. All statistical analyses were performed using SPSS 
Statistics software version 23.0 (IBM Corp., Armonk, NY, 
USA).
RESULTS
In total, 345 patients who underwent RP and received 
SADT contributed to this study. Basic characteristics of 
this cohort are displayed in Table 1. The median age was 
67 years, and the median BMI was 24.2 kg/m
2
. Initial me-
dian PSA level was 10.9 ng/ml. A PSA level above 20 ng/ml 
was reported in 62 patients (18.6%). Two-hundred sixteen 
(216) patients (62.6%) were considered high-risk PC pa-
tients as classified using the D’Amico risk classification. 
After RP, 259 (75.1%) patients had T3a PC, while the re-
maining 24.9% of patients were T3b or T4 PC. A Gleason 
score above 9 was observed in 52 patients (15.1%) after RP. 
A positive surgical margin was recorded for 261 patients 
(75.7%). Most SADT was performed using a luteinizing 
hormone-releasing hormone (LHRH) agonist with or with-
out anti-androgen agents. SADT by anti-androgen only 
was provided in only 45 patients (13.0%). 
In the univariable and multivariable Cox regression 
analyses for distant metastasis-free survival (DMFS), a 
Gleason score ≥9 was significantly associated with DMFS 
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TABLE 2. Univariable and multivariable analysis of factors associated with distant metastasis-free survival
Variable
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Age 0.969 (0.918-1.023) 0.253 　 　
BMI 0.984 (0.842-1.151) 0.843 
Prostate volume measure by TRUS 1.020 (0.997-1.044) 0.090 
PSA 0.110 
   <20 1 (ref)
   ≥20 0.311 (0.744-1.303)
Pathologic T stage 0.173 
   T3a 1 (ref)
   T3b or T4 1.670 (0.799-3.489)
Pathologic Gleason score <0.001 <0.001
   <9 1 (ref) 1 (ref)
   ≥9 4.915 (2.422-9.977) 4.145 (2.008-8.555)
Positive surgical margin 0.646 (0.304-1.375) 0.257 
PSA doubling time 0.954 (0.874-1.042) 0.296 
Salvage radiotherapy 0.487 (0.240-0.991) 0.047 0.450 (0.220-0.918) 0.028
Salvage ADT <0.001 <0.001
   Early (PSA at salvage ADT <0.5) 1 (ref) 1 (ref)
   Late (PSA at salvage ADT ≥0.5) 0.090 (0.031-0.257) 0.108 (0.037-0.310)
ADT: androgen deprivation therapy, BMI: body mass index, PSA: prostate specific antigen, PSM: positive surgical margin, TRUS: trans-
rectal ultrasonography.
TABLE 3. Univariable and multivariable analysis of factors associated with prostate cancer-specific survival
Variable
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Age 1.012 (0.919-1.115) 0.804 　 　
BMI 0.861 (0.661-1.121) 0.266 




Pathologic T stage 0.037 0.424 
T3a 1 (ref) 1 (ref)
T3b or T4 3.544 (1.078-11.653) 1.671 (0.475-5.878)
Pathologic Gleason score <0.001 0.001 
<9 1(ref) 1 (ref)
≥9 9.944 (2.910-33.984) 7.549 (2.193-25.983)
Positive surgical margin 1.178 (0.312-4.456) 0.809
PSA doubling time 0.840 (0.677-1.043) 0.114 
Salvage radiotherapy 0.301 (0.087-1.034) 0.056 0.276 (0.080-0.949) 0.041 
Salvage ADT 0.013 0.028 
Early (PSA at salvage ADT <0.5) 1 (ref) 1 (ref)
Late (PSA at salvage ADT ≥0.5) 0.074 (0.009-0.580) 0.098 (0.012-0.776)
ADT: androgen deprivation therapy, BMI: body mass index, PSA: prostate specific antigen, PSM: positive surgical margin, TRUS: 
transrectal ultrasonography.
(hazard ratio [HR] 4.145, 95% confidence interval [CI] 
2.008-8.555), as shown in Table 2. Salvage radiotherapy 
was also associated with DMFS (HR 0.450, 95% CI 
0.220-0.918). Early SADT was significantly associated 
with improved DMFS (HR 0.108, 95% CI 0.037-0.310). The 
analysis of PC-specific survival (PCSS) is shown in Table 
3. A high Gleason score was associated with PCSS (HR 
7.549, 95% CI 2.193-25.983). Early SADT was also asso-
ciated with improved PCSS (HR 0.098, 95% CI 0.012- 
0.776). Although salvage radiotherapy was only margin-
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TABLE 4. Univariable and multivariable analysis of factors associated with overall survival
Variable　
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Age 1.116 (1.050-1.186) <0.001 1.129 (1.057-1.205) <0.001
BMI 1.030 (0.885-1.198) 0.705 




Pathologic T stage 0.245 
T3a 1 (ref)
T3b or T4 1.515 (0.752-3.055)
Pathologic Gleason score 0.002 0.041 
<9 1 (ref) 1 (ref)
≥9 3.054 (1.519-6.141) 2.134 (1.030-4.423)
Positive surgical margin 0.685 (0.334-1.404) 0.301 
PSA doubling time 1.001 (0.960-1.043) 0.961 
Salvage radiotherapy 1.027 (0.509-2.071) 0.942 
Salvage ADT 0.010 0.006 
Early (PSA at salvage ADT <0.5) 1 (ref) 1 (ref)
Late (PSA at salvage ADT ≥0.5) 0.399 (0.197-0.806) 0.355 (0.169-0.747)
ADT: androgen deprivation therapy, BMI: body mass index, PSA: prostate specific antigen, PSM: positive surgical margin, TRUS: trans-
rectal ultrasonography.
ally related to PCSS in the univariable analysis (p=0.056, 
HR 0.301, 95% CI 0.087-1.034), it was associated with im-
proved PCSS in multivariable analysis (HR 0.276, 95% CI 
0.080-0.949). In Cox regression analysis for overall surviv-
al (OS), OS was associated with older age (HR 1.129, 95% 
CI 1.057-1.205), higher Gleason score (HR 2.134, 95% CI 
1.030-4.423) and early SADT (HR 0.355, 95% CI 0.169- 
0.747), as shown in Table 4. Collinearity had minimal im-
pact on variables. The variance inflation factor grew from 
1.035 to 1.158.
DISCUSSION
This report suggests an impact of early SADT on survival 
in patients with non-organ confined PC. In this study, early 
SADT was associated with improved DMFS, PCSS and OS. 
Current guidelines recommend ADT after RP in node-pos-
itive PC.
2
 Messing et al.
11
 reported that immediate ADT af-
ter RP and pelvic lymphadenectomy improved OS and PCSS. 
Nevertheless, especially in node-negative PC, the effect 
and timing of ADT after RP has remained controversial. 
Adjuvant ADT showed improvements in PCSSand sys-
temic progression-free survival after RP in a study re-
ported by Siddiqui et al.
12
 However, they reported that the 
benefits of ADT were lost in the salvage setting. In another 
study, adjuvant ADT had positive impacts on biochemical 
progression-free survival and PCSS in T3bN0 PC, but did 
not show a positive effect on OS.
13
 
ADT as a salvage treatment method is still under inves-
tigation with regard to its impacts and optimal timing. 
Moul et al. investigated the effect of early ADT after RP for 
PSA recurrence. They suggested that early ADT could de-
lay clinical metastasis of PC, but only for advanced PC 
where the Gleason score was >7 or that PSA doubling time 
was less than 12 months. They defined “early” ADT as ther-
apy initiated before clinical metastasis was confirmed.
14
 
The primary end point of that study was clinical meta-
stasis, not OS or PCSS, which might be a limitation. 
Taguchi et al reported that SADT provided before reaching 
PSA levels of 0.2 ng/mL could delay biochemical recur-
rence.
15
 However, this study included a relatively small co-
hort and could not demonstrate a benefit of early SADT for 
OS or PCSS. 
In another study reported in 2016 by Duchesne et al,
16
 
SADT initiated immediately after a PSA relapse sig-
nificantly improved OS compared with delayed SADT. 
They investigated 293 men with PC. Immediate SADT 
showed better 5-year OS than did delayed SADT (86.4% vs. 
91.2%) and did not exhibit differences in treatment-related 
adverse events. However, this study included patients 
with PC after variable local therapy, including RP and ra-
diotherapy, and patients without local definite treatments 
due to patient’s age or comorbidity. These inclusions may 
have affected the study’s results.
In previous studies, early SADT in high-risk patients 
with short PSA doubling time or high Gleason score im-
proved survival.
7
 However, its timing remains contro-
versial. In our previous study, we demonstrated the impact 
of early SADT that was initiated before meeting the clinical 
definition of biochemical recurrence.
17
 We suggested that 
early SADT had benefits in PCSS in non-organ confined 
PC. However, we did not investigate OS as an end point in 
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that study. Moreover, early SADT initiated before bio-
chemical recurrence was not associated with favorable 
PCSS. This result might be due to the large number of 
low/intermediate risk groups and patients with Gleason 
scores <8. These baseline characteristics made is difficult 
to make an association between PCSS and SADT.  
In this study, we tried to suggest an optimal cut-off value 
for early SADT. We proposed this cut-off value based on our 
clinical experience. We investigatedvarious levels of PSA, 
and we found that it was challenging to make significant 
associations between survival and SADT when PSA levels 
was lower than 0.5 ng/mL. This finding may be related with 
the indolent course of localized non-metastatic PC. 
The advancement of imaging tools used to detect recur-
rences and metastases could influence early salvage in-
terventions. Prostate-specific membrane antigen (PSMA) 
positron emission tomography-computed tomography 
(PET-CT) resulted in a major improvement in patients 
with biochemical recurrence.
18
 This modality can detect re-
currence or metastases with more sensitivity, thereby po-
tentially reducing incidence of non-metastatic recurrence. 
This advancements highlight the potential benefits of ear-
ly SADT as an intervention for metastatic disease.
This study has a few limitations. First, it is a retro-
spective study with data collected from a single institution. 
A prospective, multi-institutional, randomized study is 
needed to confirm our hypothesis. Second, we assumed cut- 
off values based on our clinical experience, but a statisti-
cally determined PSA cut-off level is necessary for more ac-
curate outcomes. Also, we did not analyze castration-re-
sistant prostate cancer (CRPC) that is one of the important 
stages in PC. We will try to investigate the association be-
tween SADT and the development of CRPC in a future 
study. Last, we did not investigate any side effects of ADT, 
like cardiovascular disease or diabetes. Physicians should 
consider these possible side effects when considering SADT.
19
Despite these limitations, we have suggested optimal 
cut-off values for early SADT that were associated with im-
proved survival. This intervention showed favorable rela-
tionships for metastasis and OS. Patients may feel anxious 
when their PSA level rises, so physicians could consider 
early SADT as a salvage treatment or radiotherapy is PSA 
level increases are observed.
In conclusion, early SADT was associated with improved 
DMFS, PCSS, and OS in non-organ confined PC after RP. 
Thus, physicians may wish to consider early SADT after 
RP in patients with non-organ confined PC.
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